What is HC Wainwright’s Estimate for DNTH FY2024 Earnings?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($3.06) per share for the year, down from their previous estimate of ($2.33). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million.

A number of other equities research analysts have also issued reports on the stock. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price for the company. Wedbush decreased their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Raymond James raised their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Trading Down 4.8 %

NASDAQ:DNTH opened at $26.35 on Thursday. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The company has a market cap of $779.88 million, a PE ratio of -10.54 and a beta of 1.84. The company’s 50 day moving average is $27.70 and its two-hundred day moving average is $26.64.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently bought and sold shares of DNTH. Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth approximately $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics in the 1st quarter valued at about $69,990,000. Great Point Partners LLC raised its stake in shares of Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after acquiring an additional 132,929 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Dianthus Therapeutics in the first quarter valued at approximately $11,251,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.